Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Status:
Not yet recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.

Phase 3

EMS